Abstract
UNITAID supports market-based interventions to improve access to medicines, diagnostics and preventive commodities for human immunodeficiency virus (HIV), tuberculosis and malaria. To help identify market-based interventions, UNITAID analyses the market of commodities of interest. These analyses, or landscapes, provide an overview of medicines on the market and in the pipeline, highlight critical market shortcomings and the underlying reasons for market failures, and identify potential strategies to correct them.
The Hepatitis C medicines technology and market landscape, published in February 2015, surveyed the state of technologies for the treatment of hepatitis C virus (HCV), as well as market dynamics that affect the affordability and accessibility of HCV therapeutics. HCV treatment falls within the ambit of UNITAID’s mission because it is a major HIV coinfection and an important cause of morbidity and mortality among people living with HIV. Strategic Objective 3 of the UNITAID Strategy 2013−2016 specifically refers to viral hepatitis, notably hepatitis B and C.
